Shepherd Kaplan Krochuk

Shepherd Kaplan Krochuk, LLC is an employee-owned investment advisory firm based in Boston, Massachusetts, founded in 2001. The firm specializes in providing fiduciary management and investment services, focusing on pooled investment vehicles and investment companies. With over $6 billion in assets under management, Shepherd Kaplan Krochuk offers a range of services, including the management of equity and balanced mutual funds, hedge funds, and separate client-focused equity portfolios. The firm utilizes both fundamental and quantitative analysis to invest primarily in value stocks across global public equity and fixed income markets. By leveraging a team of experienced professionals and a proprietary technology platform, Shepherd Kaplan Krochuk aims to deliver institutional-level capabilities while maintaining a high standard of client service.

Stephen Brackett

Founder

8 past transactions

Trilio

Series B in 2022
Trilio specializes in data protection solutions for Kubernetes, OpenStack, and Red Hat Virtualization environments. Its flagship product, TrilioVault, enables cloud infrastructure operators and developers to recover from disasters, migrate workloads, and move applications between different infrastructures or software distributions.

WindGap Medical

Series B in 2022
Founded in 2011, WindGap Medical specializes in the development and manufacturing of compact epinephrine autoinjectors for treating anaphylaxis. Headquartered in Watertown, Massachusetts.

Etiometry

Series A in 2021
Etiometry is a provider of advanced patient monitoring software and analytics designed for hospital intensive care units (ICUs). Its platform aggregates and integrates healthcare data, allowing clinicians to access comprehensive clinical information on a single screen. This functionality enhances communication among care teams and facilitates the analysis of optimal treatment courses for ICU patients. The software comprises three integrated components that offer critical insights for immediate patient care, track the trajectory of patient conditions, and estimate risks associated with compromised health. Additionally, it archives data to support research and quality improvement initiatives, ultimately enabling healthcare institutions to recognize subtle changes in patient conditions promptly, thereby avoiding complications and expediting recovery.

Trilio

Series B in 2020
Trilio specializes in data protection solutions for Kubernetes, OpenStack, and Red Hat Virtualization environments. Its flagship product, TrilioVault, enables cloud infrastructure operators and developers to recover from disasters, migrate workloads, and move applications between different infrastructures or software distributions.

NanoDx

Series C in 2020
NanoDx is a medical device company developing portable, point-of-care products for detecting traumatic brain injuries, including concussions. Its handheld devices provide rapid results, enabling timely treatment decisions and potentially reducing unnecessary head scans.

Peak Capital Management

Acquisition in 2020
PCM develops disciplined, rules-based investment strategies designed to evaluate risk on a daily basis and adapt accordingly. PCM also advises high net worth families, pension and profit sharing plans, charitable organizations, and third-party advisors through portfolio management, research, and outsourced chief investment officer capabilities.

WindGap Medical

Corporate Round in 2019
Founded in 2011, WindGap Medical specializes in the development and manufacturing of compact epinephrine autoinjectors for treating anaphylaxis. Headquartered in Watertown, Massachusetts.

EnGeneIC

Series B in 2015
EnGeneIC Ltd is a biopharmaceutical company based in Lane Cove West, Australia, focused on developing innovative methods for the targeted delivery of cancer therapies. The company has created the EnGeneIC Dream Vector (EDV), a cyto-immunotherapy platform that employs antibody-targeted, bacterially derived, non-living nano cells. This technology enables the precise release of high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into tumor cells. EnGeneIC aims to enhance the efficacy of cancer treatments while reducing toxicity, offering potential solutions for drug-resistant cancers. Established in 2000, the company serves various markets, including Australia, Singapore, Japan, and India.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.